Division of Health Policy and Management, Department of Public Health Sciences and Associate Director, Center for Healthcare Policy and Research, 2103 Stockton Blvd, Sacramento, CA, 95817, USA.
BMC Cancer. 2019 Jun 7;19(1):552. doi: 10.1186/s12885-019-5779-x.
Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.
To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression.
Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving).
Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.
经济评估通常伴随着新治疗方法或干预措施的试验；然而，回归方法及其在成本效益数据分析方面的优势并未得到广泛认可。
为了说明基于回归的经济评估，我们回顾了加拿大癌症试验组经济分析委员会进行的一项成本效益分析，并实施了净效益回归。
净效益回归为个人水平数据的成本效益分析提供了一种简单的选择。通过将经济评估置于回归框架中，基于回归的技术可以促进分析，并为常见挑战（例如，需要调整潜在混杂因素、确定关键患者亚组，以及/或总结“具有挑战性”的发现，如更有效的治疗方案有可能节省成本）提供简单的解决方案。
基于患者水平数据（例如来自临床试验）的经济评估可以使用净效益回归来促进分析并增强结果。
